drisapersen

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
024620122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated efficacy and safety of subcutaneous… (More)
Is this relevant?
2016
2016
BACKGROUND Drisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional… (More)
  • table 1
Is this relevant?
2015
2015
Antisense oligonucleotide (AO)-mediated exon-skipping therapeutics shows great promise for Duchenne muscular dystrophy (DMD… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects… (More)
Is this relevant?
2014
2014
Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein due… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2014
2014
On 20 September 2013, GlaxoSmithKline (GSK) and Prosensa announced that GSK’s Phase III clinical trial (NCT01254019) of… (More)
Is this relevant?
2014
2014
Chronic administration of drisapersen, a 2'-OMe phosphorothioate antisense oligonucleotide (AON) to mice and monkeys resulted in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Duchenne muscular dystrophy (DMD), the most common inherited form of muscular dystrophy, is a devastating muscle-wasting disease… (More)
  • figure 1
Is this relevant?
2012
2012
For Duchenne muscular dystrophy (DMD), the most common form of a group of musclewasting diseases, substantially effective… (More)
Is this relevant?